Clinical trials: Congestive Heart Failure Chronic
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction
The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction
- Trial name
- NCT03281122
- Testing
- BMS-986224
- Where
- 18 sites in Czechia, Netherlands and 3 more
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Systolic Heart Failure
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release…
- Trial name
- FIRST (NCT02188082)
- Testing
- IvabRadine hemisulfate Sustained-release Tablets
- Where
- 12 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Heart Failure
ALLEVIATE-HF-HD Study
Patients with heart failure and reduced left ventricular ejection fraction (HFrEF, EF 25-39%), or mid-range left ventricular ejection fraction (HFmrEF, EF 40-49%), or preserved left ventricular ejection fraction (HFpEF, EF ≥…
- Trial name
- NCT05501652
- Testing
- ALV1System
- Where
- Georgia
- Volunteers
- 5 people
- Sponsor
- Alleviant Medical, Inc.
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Chronic Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.
- Trial name
- NCT04944706
- Testing
- Qishen Yiqi dripping pills 4 bags/time
- Where
- 16 sites in China
- Volunteers
- 225 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure
ALLEVIATE-HFrEF Study
Patients with heart failure and reduced left ventricular ejection fraction (HFrEF, EF ≤ 40%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using…
- Trial name
- NCT05133089
- Testing
- ALV1 System
- Where
- Georgia
- Volunteers
- 5 people
- Sponsor
- Alleviant Medical, Inc.
Heart Failure
Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product
The proposed pilot study aims to gain experience with the first clinical use of the to-be marketed drug-device combination product, the sc2Wear Furosemide Combination Product and to assess methods and procedures for evaluation of…
- Trial name
- NCT02804035
- Testing
- sc2Wear Furosemide
- Volunteers
- 27 people
- Sponsor
- scPharmaceuticals, Inc.
Heart Failure NYHA Class III, Heart Failure
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure.
- Trial name
- LOWER-PAP (NCT06783335)
- Testing
- Cordella PA Sensor System, Standard of Care Pharmacologic Therapy
- Where
- United States
- Volunteers
- 2,150 people
- Sponsor
- Endotronix, Inc.
Cardiovascular Disease
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects
Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration
- Trial name
- NCT04686591
- Testing
- AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL), [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Heart Failure
South Korean Pitavastatin Heart Failure Study
We want to evaluate the utility of statins on heart function according to potency. Patients with chronic ischemic heart failure are administered pitavastatin 4mg or pravastatin 10mg for 52 weeks.
- Trial name
- SAPHIRE (NCT00701285)
- Testing
- pitavastatin, pravastatin
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- JW Pharmaceutical
Heart Failure, ADHF
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.
- Conditions
- Heart Failure, ADHF, Chronic Heart Failure, CHF
- Trial name
- NCT01316432
- Testing
- Cenderitide
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Nile Therapeutics
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
This is an observational study in which data from people in China with chronic heart failure with reduced ejection fraction (HFrEF) who will be receiving vericiguat treatment are collected.
- Trial name
- VERI-China (NCT05728502)
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of Care (SoC)
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Heart Failure
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
- Trial name
- NCT05262764
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 1,200 people
- Sponsor
- Boehringer Ingelheim
Acute Heart Failure
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 2 (NCT01067859)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 30 sites in United States, Argentina and 7 more
- Volunteers
- 5 people
- Sponsor
- Bayer
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- REMOTE-HF (NCT07022379)
- Testing
- SGLT2 Inhibitor Use
- Where
- France
- Volunteers
- 13,660 people
- Sponsor
- Satelia
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Heart Failure
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care.
- Trial name
- PAS (NCT03970343)
- Testing
- OPTIMIZER Smart System
- Where
- 90 sites in United States
- Volunteers
- 620 people
- Sponsor
- Impulse Dynamics
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Heart Failure
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with…
- Trial name
- NCT04157751
- Testing
- Empagliflozin
- Where
- 118 sites in United States, Belgium and 13 more
- Volunteers
- 530 people
- Sponsor
- Boehringer Ingelheim